Home › Companies

All companies

264 clinical-stage companies. Search or filter to narrow the list.

Ticker Company Therapeutic areas Lead stage Mkt cap Programs
FDMT 4D Molecular Therapeutics OphthalmologyRespiratory Rare Phase 3 $608M 5
AARD Aardvark Therapeutics DermatologyMetabolic+1 Rare Phase 3 $25.2M 3
ABVX Abivax Immunology Phase 3 $7.19B 2
ABSI Absci DermatologyGI/Hepatology+1 Phase 1 $1.31B 6
ACIU AC Immune Neurology Rare Phase 3 $210M 11
QUIT Achieve Life Sciences — NDA Submitted $673M 2
ACRS Aclaris Therapeutics DermatologyGI/Hepatology+1 Rare Phase 2 $536M 7
ACRV Acrivon Therapeutics GI/HepatologyOncology Rare Phase 2 $61.4M 9
ACTU Actuate Therapeutics Oncology Phase 2 $15.2M 4
ABOS Acumen Pharmaceuticals Neurology Phase 2 $16.6M 4
ADAG Adagene Oncology Phase 2 $99.4M 10
ADCT ADC Therapeutics Oncology Approved $172M 5
ACET Adicet Bio ImmunologyNeurology+2 Rare Phase 1 $26.0M 8
ADMA Adma Biologics ImmunologyInfectious Disease Rare Approved $3.02B 4
AGIO Agios Pharmaceuticals HematologyMetabolic Rare Approved $1.79B 7
AGMB Agomab Therapeutics ImmunologyRespiratory Rare Phase 2 $292M 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare Approved $111M 10
AKTS Aktis Oncology Oncology Phase 1 $910M 10
ALDX Aldeyra Therapeutics DermatologyOncology+1 NDA Submitted $41.9M 5
ALLO Allogene Therapeutics ImmunologyOncology Rare Phase 2 $256M 10
DRTS Alpha Tau Medical Oncology Phase 2 $1.12B 6
ATHE Alterity Therapeutics Neurology Rare Phase 2 $35.7M 2
ALT Altimmune GI/HepatologyMetabolic+1 Phase 3 $298M 3
ANRO Alto Neuroscience Neurology Phase 2 $999M 6
ALMS Alumis DermatologyImmunology+1 Phase 3 $628M 5
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare Phase 3 $3.54B 5
ANTX AN2 Therapeutics HematologyInfectious Disease+1 Rare Phase 2 $161M 6
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare Approved $1.36B 9
ANIX Anixa Biosciences Oncology Phase 1 $92.8M 3
ANNX Annexon HematologyNeurology+2 Rare Phase 3 $662M 6
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare Phase 2 — 9
APVO Aptevo Therapeutics Oncology Phase 1 $1.6M 8
RCUS Arcus Biosciences DermatologyImmunology+1 Phase 3 $2.36B 8
ARDX Ardelyx GI/HepatologyRenal Approved $799M 4
AVBP ArriVent BioPharma Oncology Phase 3 $553M 7
ARTV Artiva Biotherapeutics Oncology Phase 1 $191M 6
ARVN Arvinas NeurologyOncology Rare Approved $447M 10
ATAI Atai Beckley Neurology Phase 2 $2.73B 5
AUTL Autolus Therapeutics HematologyImmunology+3 Rare Approved $290M 12
AXSM Axsome Therapeutics Neurology Rare Approved $7.15B 15
BEAM Beam Therapeutics HematologyMetabolic+1 Rare Phase 2 $2.14B 6
BLTE Belite Bio MetabolicOphthalmology Rare NDA Submitted $6.35B 6
BCAX Bicara Therapeutics Oncology Phase 2 $637M 4
BCYC Bicycle Therapeutics Oncology Phase 2 $224M 4
BIOA BioAge Labs CardiovascularOphthalmology Phase 2 $234M 2
BCRX Biocryst Pharmaceuticals DermatologyImmunology+1 Rare Approved $1.93B 4
BMEA Biomea Fusion MetabolicOncology Phase 2 $35.5M 4
BDTX Black Diamond Therapeutics Oncology Phase 2 $82.8M 4
BCTX BriaCell Therapeutics Oncology Phase 3 $30.7M 8
BBOT BridgeBio Oncology Therapeutics Oncology Phase 1 $156M 6
CCCC C4 Therapeutics Oncology Phase 2 $332M 2
CABA Cabaletta Bio DermatologyImmunology+2 Rare Phase 2 $220M 8
CAMP Camp4 Therapeutics — Phase 1 $251M 1
CADL Candel Therapeutics Oncology Phase 3 $424M 4
CAPR Capricor Therapeutics Infectious DiseaseNeurology Rare NDA Submitted $489M 2
CRDL Cardiol Therapeutics Cardiovascular Rare Phase 3 $124M 4
CRBU Caribou Biosciences — — $36.8M 0
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare Phase 3 $187M 4
CLDX Celldex Therapeutics DermatologyImmunology+1 Phase 3 $2.20B 6
CLRB Cellectar Biosciences Oncology Phase 2 $9.2M 7
IPSC Century Therapeutics ImmunologyMetabolic+1 Rare Phase 1 $249M 9
CRVO CervoMed Neurology Rare Phase 2 $22.7M 4
CGON CG Oncology Oncology NDA Submitted $7.05B 1
CMMB Chemomab Therapeutics GI/HepatologyImmunology+1 Rare Phase 2 $13.2M 4
CING Cingulate Neurology NDA Submitted $70.6M 1
CLNN Clene Neurology Rare NDA Submitted $46.4M 5
CLYM Climb Bio HematologyImmunology+1 Rare Phase 2 $574M 8
COGT Cogent Biosciences HematologyOncology Rare NDA Submitted $4.85B 7
CGTX Cognition Therapeutics Neurology Phase 2 $59.9M 2
CHRS Coherus Oncology Oncology Approved $74.0M 5
CMPS COMPASS Pathways Neurology NDA Submitted $1.13B 3
CMPX Compass Therapeutics Oncology Phase 2 $109M 15
CGEN Compugen Oncology Phase 3 $191M 7
CNTB Connect Biopharma Respiratory Phase 2 $37.3M 4
CTNM Contineum Therapeutics NeurologyRespiratory Rare Phase 2 $375M 4
CRVS Corvus Pharmaceuticals DermatologyOncology+1 Rare Phase 3 $858M 7
COYA Coya Therapeutics Neurology Rare Phase 2 $70.8M 6
CBIO Crescent Biopharma Oncology Phase 2 $507M 10
CRNX Crinetics Pharmaceuticals MetabolicOncology Rare Approved — 6
CUE Cue Biopharma ImmunologyOncology Phase 2 $23.7M 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare NDA Submitted $602M 10
CYDY CytoDyn NeurologyOncology Phase 2 $367M 3
CTMX CytomX Therapeutics Oncology Phase 1 $423M 7
DBVT DBV Technologies Immunology NDA Submitted $3.14B 2
DFTX Definium Therapeutics Neurology Phase 3 $4.02B 4
IRON Disc Medicine GI/HepatologyHematology+2 Rare Phase 3 $3.49B 9
DYN Dyne Therapeutics MetabolicNeurology Rare NDA Submitted $3.00B 10
EWTX Edgewise Therapeutics Cardiovascular Phase 2 $4.60B 3
EIKN Eikon Therapeutics Oncology Phase 2 $279M 13
ELDN Eledon Pharmaceuticals ImmunologyMetabolic+1 Rare Phase 2 $167M 3
ELTX Elicio Therapeutics Oncology Phase 2 $40.5M 6
ELOX Eloxx Pharmaceuticals DermatologyRenal Rare Phase 2 $48.0M 4
ENTA Enanta Pharmaceuticals DermatologyImmunology+2 Approved $253M 8
ELVN Enliven Therapeutics Oncology Phase 1 $3.45B 1
ENTX Entera Bio GI/HepatologyMetabolic Rare Phase 2 $522M 4
ERAS Erasca Oncology Phase 1 $4.87B 5
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare Approved $1.84B 17
EVMN Evommune DermatologyImmunology+1 Phase 2 $290M 6
EXEL Exelixis CardiovascularOncology Approved $16.7B 23
EYPT EyePoint Ophthalmology Phase 3 $34.1M 2
FATE Fate Therapeutics ImmunologyOncology+1 Rare Phase 2 $124M 10
FHTX Foghorn Therapeutics Oncology Preclinical $110M 4
FBRX Forte Biosciences DermatologyGI/Hepatology Phase 2 — 3
FBIO Fortress Biotech DermatologyHematology+4 Rare Approved $61.4M 16
GUTS Fractyl Health Metabolic Phase 3 $12.8M 1
GANX Gain Therapeutics MetabolicNeurology Rare Phase 1 $52.5M 5
GNLX Genelux Oncology Phase 3 $96.1M 3
GERN Geron Oncology Approved $644M 3
GHRS GH Research NeurologyWomen's Health Phase 2 $1.25B 4
GOSS Gossamer Bio Cardiovascular Rare NDA Submitted $67.5M 4
GRCE Grace Therapeutics Neurology NDA Submitted $36.2M 1
GLSI Greenwich LifeSciences Oncology Phase 3 $274M 1
HRMY Harmony Biosciences MetabolicNeurology Rare Approved $1.94B 17
HROW Harrow Ophthalmology Rare Approved $1.11B 15
HELP Helus Pharma Neurology Phase 3 $575M 3
IDYA IDEAYA Biosciences Oncology NDA Submitted $2.65B 15
IMTX Immatics Oncology Phase 3 $958M 8
IMMX Immix Biopharma Hematology Rare Phase 1 $603M 1
IMRX Immuneering Oncology Phase 3 $224M 5
IMUX Immunic GI/HepatologyNeurology Phase 3 $116M 4
IBRX ImmunityBio Infectious DiseaseOncology Approved $6.66B 17
IMCR Immunocore DermatologyInfectious Disease+2 Approved $1.44B 12
IMNM Immunome Oncology Rare NDA Submitted $2.03B 9
IMVT Immunovant ImmunologyNeurology Rare Phase 3 $6.87B 4
INAB IN8bio ImmunologyOncology Phase 1 $8.9M 4
IXHL Incannex Healthcare NeurologyRespiratory Phase 2 $21.8M 2
INBX Inhibrx Biosciences Oncology NDA Submitted $1.10B 6
INMB Inmune Bio Dermatology Rare Phase 3 $29.7M 1
INSM Insmed CardiovascularImmunology+3 Rare Approved $26.7B 15
NTLA Intellia Therapeutics CardiovascularImmunology Rare NDA Submitted $1.37B 3
IVVD Invivyd Infectious Disease Approved $152M 5
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare Approved $4.49B 29
JBIO Jade Biosciences ImmunologyRenal Rare Phase 2 $1.07B 4
JANX Janux Therapeutics Oncology Phase 1 $655M 4
KAPA Kairos Pharma Oncology Phase 2 $1.9M 12
KZIA Kazia Therapeutics NeurologyOncology Rare Phase 2 $60.7M 13
KROS Keros Therapeutics NeurologyOncology Rare Phase 3 $222M 5
KPRX Kiora Pharmaceuticals Ophthalmology Rare Phase 3 $4.1M 4
KOD Kodiak Sciences Ophthalmology Phase 3 $6.33B 8
KURA Kura Oncology MetabolicOncology Approved $688M 13
KYMR Kymera Therapeutics DermatologyImmunology+1 Rare Phase 2 $10.4B 5
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare NDA Submitted $297M 6
LRMR Larimar Therapeutics Neurology Rare NDA Submitted $313M 1
LBRX LB Pharmaceuticals Neurology Phase 3 $1.30B 3
LEGN Legend Biotech Oncology Rare Approved $3.12B 17
LENZ LENZ Therapeutics Ophthalmology Approved $110M 1
LXEO Lexeo Therapeutics CardiovascularNeurology Rare Phase 2 $236M 12
LCTX Lineage Cell Therapeutics MetabolicNeurology+1 Rare Phase 2 $207M 13
LQDA Liquidia CardiovascularImmunology+1 Rare Approved $5.11B 9
LGVN Longeveron CardiovascularNeurology Rare Phase 2 $7.1M 3
MAIA MAIA Biotechnology Oncology Phase 3 $77.2M 8
MPLT MapLight Therapeutics Neurology Phase 2 $365M 3
MRKR Marker Therapeutics Oncology Phase 1 $14.0M 5
MAZE Maze Therapeutics MetabolicRenal Rare Phase 2 $1.80B 4
MBX MBX Biosciences Metabolic Rare Phase 3 $2.64B 4
MDNAF Medicenna Therapeutics Oncology Phase 2 $14.8M 10
MGTX MeiraGTx ImmunologyMetabolic+2 Rare Phase 3 $827M 16
MESO Mesoblast CardiovascularGI/Hepatology+2 Rare Approved $1.54B 5
MIST Milestone Pharmaceuticals Cardiovascular Approved $51.4M 2
MLYS Mineralys Therapeutics CardiovascularRenal+1 NDA Submitted $1.28B 3
INKT MiNK Therapeutics ImmunologyOncology+1 Rare Phase 2 $47.7M 8
MBRX Moleculin Biotech Oncology Phase 2 $7.3M 9
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare Phase 2 $775M 7
MLTX MoonLake Immunotherapeutics DermatologyImmunology Rare NDA Submitted $957M 4
NKTR Nektar Therapeutics DermatologyImmunology+2 Phase 3 $1.23B 11
NGEN NervGen Pharma Neurology Phase 3 $211M 3
NGNE Neurogene Neurology Rare Phase 3 $478M 1
NRSN NeuroSense Therapeutics Neurology Rare Phase 2 $2.9M 3
NAMS NewAmsterdam Pharma CardiovascularMetabolic+1 NDA Submitted $2.33B 6
NKTX Nkarta ImmunologyNeurology+1 Rare Phase 1 $89.6M 8
NBP NovaBridge Biosciences OncologyOphthalmology Phase 2 $95.4M 7
NRXP NRX Pharmaceuticals Neurology Rare Approved $109M 11
NRIX Nurix Therapeutics ImmunologyNeurology+1 Phase 3 $1.56B 13
NVCT Nuvectis Pharma HematologyOncology+1 Rare Phase 3 $660M 9
OCGN Ocugen Infectious DiseaseOphthalmology Rare Phase 3 $257M 12
OCS Oculis Holding NeurologyOphthalmology Rare Phase 3 $418M 5
OLMA Olema Pharmaceuticals Oncology Phase 3 $633M 3
OMER Omeros HematologyNeurology+2 Rare Approved $1.04B 6
ONCY Oncolytics Biotech Oncology Phase 2 $51.7M 4
OKUR OnKure Therapeutics Oncology Preclinical $104M 2
IRD Opus Genetics Ophthalmology Rare Approved $391M 12
ORIC Oric Pharmaceuticals Oncology Phase 3 $831M 5
ORKA Oruka Therapeutics DermatologyImmunology Rare Phase 2 $6.53B 7
OTLK Outlook Therapeutics Ophthalmology Approved $87.9M 3
OVID Ovid Therapeutics Neurology Rare Phase 2 $419M 4
PTN Palatin Technologies ImmunologyMetabolic+1 Phase 3 $9.5M 5
PALI Palisade Bio Immunology Phase 2 $181M 3
KTTA Pasithea Therapeutics NeurologyOncology Rare Phase 1 $16.0M 4
PEPG PepGen Neurology Rare Phase 2 $269M 1
CATX Perspective Therapeutics Oncology Phase 1 $104M 5
PHIO Phio Pharmaceuticals Oncology Phase 1 $8.6M 4
PMVP PMV Pharmaceuticals Oncology Phase 2 $92.2M 7
PYPD PolyPid Infectious DiseaseMetabolic+1 NDA Submitted $138M 4
DTIL Precision Biosciences Infectious DiseaseMetabolic+1 Rare Phase 1 $197M 5
PRLD Prelude Therapeutics HematologyOncology Rare Phase 1 $266M 3
PRME Prime Medicine GI/HepatologyRespiratory Rare Phase 1 $699M 3
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare Phase 2 $4.8M 7
PMN ProMIS Neurosciences Neurology Rare Phase 1 $28.9M 9
PRQR ProQR Therapeutics MetabolicNeurology Rare Phase 1 $163M 7
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare Approved $8.14B 12
TARA Protara Therapeutics DermatologyMetabolic+1 Rare Phase 3 $143M 3
QTTB Q32 Bio Dermatology Phase 2 $258M 3
QNRX Quoin Pharmaceuticals DermatologyImmunology Rare Phase 2 $236M 4
RAPP Rapport Therapeutics Neurology Phase 3 $1.41B 6
RXRX Recursion Pharmaceuticals Oncology Phase 2 $1.69B 6
RNTX Rein Therapeutics Respiratory Rare Phase 2 $30.7M 1
RLAY Relay Therapeutics DermatologyOncology Rare Approved $3.64B 4
RLMD Relmada Therapeutics MetabolicNeurology+1 Rare Phase 2 $321M 4
REPL Replimune Group Oncology Approved $1.87B 5
RVPH Reviva Pharmaceuticals CardiovascularDermatology+3 Rare Phase 3 $4.7M 11
RVMD Revolution Medicines Oncology Approved $35.2B 11
RYTM Rhythm Pharmaceuticals Metabolic Rare Approved $8.08B 14
RCKT Rocket Pharmaceuticals CardiovascularImmunology Rare Approved $236M 4
SABS SAB Biotherapeutics Metabolic Phase 2 $266M 1
SGMT Sagimet Biosciences DermatologyMetabolic Phase 3 $709M 3
SANA Sana Biotechnology MetabolicOncology Phase 1 $563M 4
SRPT Sarepta Therapeutics NeurologyRespiratory Rare Approved $1.58B 11
SCYX Scynexis Infectious DiseaseRenal Rare Approved $28.4M 5
SLS SELLAS Life Sciences Group Oncology Phase 3 $3.90B 9
SEPN Septerna ImmunologyMetabolic+1 Rare Phase 1 $1.90B 5
SION Sionna Therapeutics Respiratory Rare Phase 2 $139M 5
SLDB Solid Biosciences CardiovascularNeurology Rare Phase 3 $695M 6
SPRB Spruce Biosciences Metabolic Rare Preclinical $116M 2
SYRE Spyre Therapeutics DermatologyImmunology Rare Phase 2 $8.91B 10
STOK Stoke Therapeutics Neurology Rare Phase 3 $1.73B 2
GPCR Structure Therapeutics MetabolicRespiratory Rare Phase 3 $3.90B 5
SMMT Summit Therapeutics Oncology NDA Submitted $8.53B 6
STRO Sutro Biopharma Oncology Phase 1 $148M 3
SNDX Syndax Pharmaceuticals ImmunologyOncology Rare Approved $822M 7
TNGX Tango Therapeutics Oncology Phase 1 $3.75B 5
TSHA Taysha Gene Therapies Neurology Rare Phase 3 $1.30B 4
TECX Tectonic Therapeutic Cardiovascular Rare Phase 2 $401M 4
TLX Telix Pharmaceuticals Oncology Approved $3.01B 25
TENX Tenax Therapeutics Cardiovascular Rare Phase 3 $64.7M 2
TGTX Tg Therapeutics Neurology Rare Approved $9.48B 6
TLSA Tiziana Life Sciences ImmunologyNeurology Rare Phase 2 $83.2M 5
TVTX Travere Therapeutics MetabolicRenal Rare Approved $4.91B 7
HURA TuHURA Biosciences Oncology Phase 3 $92.1M 4
TTRX Turn Therapeutics DermatologyInfectious Disease Rare Phase 2 $261M 4
TYRA Tyra Biosciences MetabolicOncology Rare Phase 2 $1.35B 5
RARE Ultragenyx Pharmaceutical CardiovascularMetabolic+1 Rare Approved $1.70B 10
UNCY Unicycive Therapeutics Renal NDA Submitted $108M 2
QURE uniQure HematologyMetabolic+1 Rare Approved $1.46B 4
UPB Upstream Bio Respiratory Phase 2 $115M 3
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare Approved $230M 27
PCVX Vaxcyte Infectious Disease Phase 3 $9.40B 7
VERA Vera Therapeutics Infectious DiseaseRenal Rare Approved $1.89B 6
VSTM Verastem Oncology Approved $934M 5
VRCA Verrica Pharmaceuticals DermatologyOncology Rare Approved $53.9M 4
VKTX Viking Therapeutics MetabolicNeurology Rare Phase 3 $3.43B 9
VIR Vir Biotechnology Infectious DiseaseOncology Rare Phase 3 $1.58B 6
VRDN Viridian Therapeutics ImmunologyOphthalmology Approved $3.41B 7
VOR Vor Biopharma ImmunologyNeurology Rare Phase 3 $1.12B 2
VYGR Voyager Therapeutics MetabolicNeurology Rare Phase 1 $94.6M 9
VTVT vTv Therapeutics HematologyMetabolic+1 Rare Phase 3 $69.4M 9
WVE Wave Life Sciences MetabolicNeurology+1 Rare Phase 2 $560M 5
XFOR X4 Pharmaceuticals — Approved $316M 2
XNCR Xencor ImmunologyNeurology+1 Rare Approved $2.59B 28
XENE Xenon Pharmaceuticals Neurology Rare NDA Submitted $3.81B 9
XERS Xeris Biopharma MetabolicNeurology Rare Approved $3.07B 4
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare NDA Submitted $1.88B 11
ZNTL Zentalis Pharmaceuticals Oncology Phase 3 $146M 1
ZURA Zura Bio DermatologyImmunology Rare Phase 2 $99.7M 4
ZYME Zymeworks OncologyRespiratory Approved $1.78B 12